https://www.selleckchem.com/products/ertugliflozin.html Moreover, when the internationally most widely used definition of recovery was applied, the recovery rate at 20 weeks of CBT-E was significantly higher (57.7%) than of TAU (36.0%). At 80 weeks, this difference was no longer significant (CBT-E 60.9%; TAU 43.6%). Furthermore, CBT-E was more effective in improving self-esteem and was also the less intensive and shorter treatment. DISCUSSION With broader use of CBT-E, the efficiency, accessibility and effectivity (on self-esteem) of treatment for EDs could be improved. © 2020 The Authors. International Journal of Eating Disorders published by Wiley Periodicals, Inc.AIM Patients with resolved hepatitis B virus (HBV) infection are at risk of HBV reactivation during treatment for hematologic malignancies. We aim to conduct a meta-analysis of the data on the efficacy of antiviral prophylaxis for the prevention of HBV reactivation in this group of patients. METHODS We conducted a systemic search of the MEDLINE and EMBASE databases to 31 January, 2019 to identify studies published in English comparing antiviral prophylaxis versus no prophylaxis in patients undergoing treatment for hematologic malignancies. The search terms used were "occult hepatitis B" or "resolved hepatitis B" AND "reactivation" AND "haematological malignancy" or "hematological malignancy" or "chemotherapy" or "immunotherapy" or "chemoimmunotherapy" or "lymphoma" or "leukemia" or "transplant". The primary outcome was reactivation of HBV infection. Pooled estimates of relative risk (RR) were calculated. RESULTS We identified 13 relevant studies with a total of 1724 patients [two randomized controlled trials (RCTs), one post hoc analysis from RCT and ten cohort studies]. There was a trend towards a lower rate of HBV reactivation with antiviral prophylaxis, but the difference was not significant (RR 0.57, 95% CI 0.23-1.40, P = 0.22). When limiting the analysis to the three prospective studies in patients